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ABSTRACT
Angiogenesis is an essential process required for tumor growth and progression. 
The Notch signaling pathway has been identified as a key regulator of the neo-
angiogenic process. Jagged-1 (Jag1) is a Notch ligand required for embryonic and 
retinal vascular development, which direct contribution to the regulation of tumor 
angiogenesis remains to be fully characterized.
The current study addresses the role of endothelial Jagged1-mediated Notch 
signaling in the context of tumoral angiogenesis in two different mouse tumor models: 
subcutaneous Lewis Lung Carcinoma (LLC) tumor transplants and the autochthonous 
Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
The role of endothelial Jagged1 in tumor growth and neo-angiogenesis was 
investigated with endothelial-specific Jag1 gain- and loss-of-function mouse mutants 
(eJag1OE and eJag1cKO). By modulating levels of endothelial Jag1, we observed that 
this ligand regulates tumor vessel density, branching, and perivascular maturation, 
thus affecting tumor vascular perfusion. The pro-angiogenic function is exerted by 
its ability to positively regulate levels of Vegfr-2 while negatively regulating Vegfr-1. 
Additionally, endothelial Jagged1 appears to exert an angiocrine function possibly 
by activating Notch3/Hey1 in tumor cells, promoting proliferation, survival and 
epithelial-to-mesenchymal transition (EMT), potentiating tumor development. These 
findings provide valuable mechanistic insights into the role of endothelial Jagged1 in 
promoting solid tumor development and support the notion that it may constitute a 
promising target for cancer therapy.
INTRODUCTION
Since Folkman’s seminal insight of treating 
cancer by cutting its blood supply [1] much effort has 
been devoted to understand the underlying molecular 
mechanisms that drive tumor angiogenesis. It is well 
established that tumor growth is restricted in an early 
avascular phase, and that, to be able to progress and 
develop it requires an angiogenic switch [2].
Tumor angiogenesis is initiated when endothelial 
cells respond to local stimuli and migrate towards the 
growing mass. This migration results in the formation 
of tubular structures that ultimately recruit perivascular 
support cells in order to create a well-established neo-
vasculature that allows tumor development and eventual 
metastization [2].
Many signaling pathways have been identified as 
key contributors to the neo-angiogenic process. Among 
them is the Notch signaling pathway, an evolutionary 
conserved signaling system that regulates proliferation, 
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differentiation, cell-fate determination, progenitor and 
stem-cell self-renewal, in both embryonic and adult 
tissues [3, 4]. The Notch pathway is composed of 5 
ligands (Jagged-1, Jagged-2, and Delta-like 1, 3, and 4) 
and 4 receptors (Notch 1–4). Ligand–receptor interactions 
promote the cleavage of the Notch receptors, releasing 
the Notch intracellular domain (NICD), which is then 
translocated to the nucleus where it binds a transcriptional 
repressor and ultimately leads to the transcription of 
downstream target genes, such as several helix–loop–helix 
transcription factors (Hey and Hes gene families among 
others) [3].
The Notch ligand, Dll4, is required for normal 
arterial patterning in the embryo [4] and has a major effect 
in solid tumor growth [5, 6]. This effect of targeting Dll4 
is apparently paradoxical as it inhibits tumor growth by 
triggering excessive angiogenesis, that results in poorly 
functional vessels [7].
However, despite the extensive characterization of 
the role of Dll4 in tumor vasculature, the contribution of 
other Notch ligands, like Jagged1, is less well studied. 
Jag1-null mouse mutants die at E11.5 due to heart defects 
and abnormal development of the yolk sac and head 
vasculature [8]. Moreover, mutations in the human JAG1 
gene cause Alagille syndrome, which comprises complex 
cardiac defects and vascular anomalies [9]. Additionally, 
in the developing retina [10] endothelial Jagged1 has been 
shown to have a pro-angiogenic function, opposite to 
that of Dll4. This pro-angiogenic function has also been 
demonstrated in an adult physiological setting, where 
it promotes wound healing by the ability to antagonize 
Dll4/Notch1 endothelial branching while positively 
regulating vascular maturation through activation of 
endothelial Notch4 and perivascular Notch3 [11]. 
Jagged1 is expressed in the vasculature, as well as in 
many other tissues. In the context of tumor angiogenesis 
two reports suggest that tumor cells expressing Jagged1 
can act in a pro-angiogenic manner: induction of the 
Notch ligand Jagged1 by growth factors (via MAPK) in 
head and neck squamous cell carcinoma was shown to 
trigger Notch activation in neighboring endothelial cells 
and promote capillary-like sprout formation [12], and 
Jagged1 expressed in breast tumor cells can influence 
tumor angiogenesis [13]. Similarly, in the context of 
lymphoma, a specific population of lymphoma cells was 
shown to up-regulate endothelial Jagged1, through the 
secretion of FGF4, which in turn up-regulates Notch2 and 
consequently Hey1 in the tumor cells promoting growth, 
aggressiveness and resistance to chemotherapy [14]. 
Finally, a specific Notch1 decoy, that blocks both Jagged 
ligands interactions with Notch1, was shown to decrease 
xenograft growth by an anti-angiogenic effect and by the 
ability to destabilize pericyte-ECs interactions [15].
Therefore, the direct role of endothelial Jagged1 in 
tumor angiogenesis has not yet been thoroughly described. 
With this purpose, we have fully characterized tumor 
growth and progression, and the associated vascular 
phenotype and cellular metabolic consequences in 
endothelial Jag1 mutants in two different mouse tumor 
models: subcutaneous Lewis Lung Carcinoma (LLC) 
tumor transplants and in the autochthonous transgenic 
adenocarcinoma of the mouse prostate (TRAMP) [16, 17].
Here we demonstrate for the first time the effect 
of directly modulating endothelial Jagged1 in tumor 
angiogenesis and growth, confirming that loss of 
endothelial Jag1 has a strong anti-angiogenic effect that 
inhibits tumor growth and the acquisition of an invasive 
phenotype. Moreover, we have shown that endothelial 
Jagged1 regulates prostatic tumor cell proliferation and 
de-differentiation by activating Notch3 and consequently 
up-regulating Hey1 in tumor cells. The results obtained 
clearly raise the possibility of applying anti-Jagged1 
therapies to cancer treatment.
RESULTS
Modulation of endothelial Jag1 interferes with the 
growth of LLC subcutaneous tumor transplants
To evaluate the contribution of endothelial Jagged1 
to tumor angiogenesis, LLC cells were subcutaneously 
implanted in the dorsum of endothelial specific Jag1 
gain- (eJag1OE) and loss-of-function mouse mutants 
(eJag1cKO). Tumor volumes (mm3) were measured 
from day seven after the subcutaneous injection until day 
fourteen.
Endothelial specific Jag1 overexpression led to 
significantly accelerated growth of subcutaneous tumors, 
from day eleven after injection, with a final tumor volume 
more than two-fold larger (1370 mm3) than that of the 
respective controls (570 mm3) (Figure 1A). In contrast, 
loss of endothelial Jag1 led to significantly delayed tumor 
growth, from day eleven after injection (Figure 1B). The 
average final tumor volume in the endothelial Jag1 loss-
of-function mutants was only 300 mm3, less than half of 
that of the respective controls (650 mm3).
Endothelial Jagged1 contributes to prostate 
cancer development and progression
After verifying that modulation of endothelial Jag1 
caused such significant alterations in the growth of LLC 
subcutaneous tumor transplants, we investigated its effect 
in an autochthonous tumor model. For this end, we crossed 
the endothelial Jag1 mutants to a mouse model of prostate 
adenocarcinoma (TRAMP) [16], which spontaneously 
develop prostatic lesions from 8 weeks of age [18]. The 
TRAMP endothelial specific Jag1 mutants, TRAMP.
eJag1OE and TRAMP.eJag1cKO, were sacrificed at 18 
and 24 weeks of age, for early and late stages of prostate 
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cancer development, and the prostates collected for 
analysis.
Endothelial specific Jag1 over-expression TRAMP 
mice presented increased prostate weights relative to 
the respective controls (TRAMP Ctrl) at both early and 
late stages of prostate tumor development (Figure 2A). 
Accordingly, loss of endothelial Jag1 caused decreased 
total prostate weights due to reduction of the tumors, 
relative to TRAMP Ctrl mice, both in early and late stages 
(Figure 2B). Noticeably, the prostate weights of TRAMP.
eJag1cKO did not differ significantly from those of WT 
animals, indicating a most considerable reduction in tumor 
growth. 
Histopathological analysis was carried out blindly 
and the tumors scored according to the following 
categories: Normal (0), prostatic intraepithelial neoplasia 
[PIN (1)], well differentiated adenocarcinoma [WDA 
(2)], moderately differentiated adenocarcinoma [MDA 
(3)], poorly differentiated adenocarcinoma [PD (4)], 
or phylloides-like cancer [PHY (5)] [18]. The prostatic 
lesions evolve in a progressive manner, with different 
lobes of the prostate presenting different stages of tumor 
development. Endothelial overexpression of Jag1 caused 
an overall acceleration of prostate cancer progression 
(Figure 2C, 2D and 2F; Suppl. Figure 1A). At an early 
stage, even though there was no statistically significant 
difference in the most common lesion score between 
TRAMP.eJag1OE and the respective controls (Figure 
2C), it was observed that, in the controls, the majority of 
animals (70%) presented lesions of PIN (Suppl. Figure 
1A), while in the eJag1OE group, the majority (85,7%) 
already had evolved to lesions of WDA. Similarly, at a late 
stage, it was observed a statistically significant difference 
in the most common lesion score (Figure 2C) between 
the mouse groups: 100% of control mice (TRAMP Ctrl) 
presented lesions of WDA and few animals progressed to 
advanced stages of prostatic adenocarcinoma (Figure 2C 
and 2D), while the TRAMP.eJag1OE group presented a 
greater percentage of animals that progressed to advanced 
stages of prostatic adenocarcinomas (Figure 2C) (33% 
lesions of MDA, 22% of PDA and 30% PHY lesions).
In contrast, TRAMP.eJag1cKO mutant mice 
presented a statistically significant inhibition of prostate 
tumor progression (Figure 2C, 2E and 2G; Suppl. Figure 
1B). At an early stage of tumor development (18wks), the 
respective control group presented a mean score of the 
most common lesion of 1.2 (Figure 2D) with 66,7% of 
animals revealing lesions of WDA (Suppl. Figure 1B), 
Figure 1: LLC transplant tumor volume in endothelial specific Jag1 mutants. A. Progression of LLC transplant tumor 
volume, from day 7 of subcutaneous injection, in endothelial specific Jag1 over-expression mutants (Tet-O-Jag Tie2-rtTA+) relative to the 
respective controls (Tet-O-Jag Tie2-rtTA-). Jag1 over-expression mutants present an accelerated growing rate of subcutaneous tumors, 
with a final tumor volume of more than double of the respective controls. B. Progression of LLC transplant tumor volume, from day 7 of 
subcutaneous injection, in endothelial specific Jag1 Knock-out mutants (Jag1lox/lox Cre+) and controls (Jag1lox/lox Cre-). Loss of Jag1 led to 
a decrease in the growing rate of subcutaneous tumors, with a final tumor volume of less than half of the respective controls. Results are 
representative of 2 independent experiments, each with n = 6 mice per group. Error bars represent SEM; * represents p < 0.05; ** represents 
p < 0.01; *** represents p < 0.001. 
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Figure 2: Modulation of endothelial Jag1 in TRAMP mice. A. Prostate weight increase (in %, relative to WT-0) in TRAMP 
Ctrl (Tet-O-Jag Tie2-rtTA-) and TRAMP.eJag1OE (Tet-O-Jag Tie2-rtTA+) mutants, in early (18 wks) and late (24 wks) stages of prostate 
tumor development. In both stages TRAMP.eJag1OE present higher prostate weight increase either relative to WT, as to TRAMP Ctrl 
mice groups. B. Prostate weight increase (in %, relative to WT-0) in TRAMP Ctrl (Jag1lox/lox Cre-) and TRAMP.eJag1cKO (Jag1lox/lox Cre+) 
mutants, in early (18 wks) and late (24 wks) stages of prostate tumor development. In both stages TRAMP.eJag1cKO present lower prostate 
weight increase than TRAMP Ctrl mice group. C. and D. Evolution of most common prostatic lesion of TRAMP.eJag1OE and TRAMP.
eJag1cKO mutants, respectively, and controls, based on histopathological classification of prostatic lesions according to the following score 
(1-5): Normal (0); prostatic intraepithelial neoplasia (PIN (1)); well differentiated adenocarcinoma (WDA (2)); moderately differentiated 
adenocarcinoma (MDA (3)); poorly differentiated adenocarcinoma (PD (4)); or phylloides-like cancer (PHY (5)). TRAMP.eJag1OE 
present a higher score evolution than controls, whereas TRAMP.eJag1cKO present a lower one. E. and F. Frequency distribution (% of 
mice) of histophatological classification of prostatic lesions at 24 weeks of age in TRAMP.eJag1OE and TRAMP.eJag1cKO, respectively, 
versus controls. G. H & E representative images of the histopathological classification in WT (no lesions), TRAMP Ctrl (WDA), TRAMP.
eJag1OE (MDA) and TRAMP.eJag1cKO (PIN) mice. Results are representative of n = 12 per mice group for each time point. Error bars 
represent SEM; * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001. 
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Figure 3: Prostate tumor vascular phenotype in TRAMP endothelial-specific Jag1 mutants. A. Representative confocal 
(one z layer) immunostaining images (40x amplification) marked for PECAM-1 (green) and SMA (red), to evaluate vascular density and 
vSMC of prostate samples. B. Percentage of vascular density (relative to control = 100%) is increased in TRAMP endothelial Jag1 over-
expression mutants as shown by PECAM-1 labeling. C. Number of endothelial branching points, demonstrating increased branching in 
TRAMP.eJag1OE relative to controls. D. Percentage of vascular smooth muscle coverage, showing increased levels of SMA on TRAMP 
eJag1OE mutant vasculature, relative to controls. E. Percentage of vascular density (relative to control=100%) is decreased in TRAMP 
endothelial Jag1 knock-out mutants. F. Number of endothelial branching points, demonstrating decreased branching in TRAMP.eJag1cKO 
relative to controls. G. Percentage of vascular smooth muscle coverage, showing decreased levels of SMA on TRAMP eJag1cKO mutant 
vasculature, relative to controls. DAPI (blue) stains nuclei. Error bars represent SEM; * represents p < 0.05; ** represents p < 0.01; *** 
represents p < 0.001.
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while the eJag1cKO mouse group presented a mean score 
of 0.3 (Figure 2D) with 44,4% animals still showing no 
lesions (Normal), and the majority (77,8%) progressing 
only to lesions of PIN (Suppl. Figure 1B). At a later stage, 
the same kind of response was observed with WDA in 
90% of control animals, while only 30% of eJag1cKO 
evolved to WDA, being the majority (90%) of this latest 
group classified mainly with lesions of PIN (Figure 2F and 
2G). 
From the analysis of the most common lesion 
per animal it was also clear that there was no statistical 
interaction between the genotype and respective control 
groups throughout the evolution of the lesions (Figure 
2C and 2D), in either TRAMP.eJag1cKO or TRAMP.
eJag1OE. This means that the effect of modulating 
endothelial Jag1 remained constant in time (evolution of 
tumor progression). 
To gain additional confirmation of the differences 
in the progression and severity of prostatic lesions we 
immunostained the prostate samples for PSMA, a known 
marker of prostate cancer progression [19]. Consistently 
with the prostate weight and histopathological 
classification data, TRAMP.eJag1OE presented very 
strong immunostaining for PSMA in the prostatic tissue, 
while TRAMP.eJag1cKO presented very weak signal, 
compared with controls (TRAMP Ctrl) (Suppl. Figure 1C).
Endothelial Jagged1 has a pro-angiogenic 
function in tumor development
Efficient modulation of endothelial Jagged1 
was achieved in our conditional gain-of-function and 
knock-out mutants as demonstrated by the increased 
and decreased Jag1 transcription levels in ECs and the 
increased and decreased fluorescence levels of Jagged1 
co-localized with PECAM-1, respectively (Suppl. Figure 
2). To address whether the altered growth of subcutaneous 
LLC tumor transplants and prostate cancer development 
and progression observed in these EC-specific mutants 
was indeed associated with altered vessel growth, the 
vascular morphology of the tumors was examined. The 
endothelium was visualized by immunostaining against 
PECAM-1, while α-SMA was used to reveal perivascular 
cell coverage and thereby analyze vessel maturation 
(Figures 3A-3G and Suppl. Figure 3).
In eJag1OE mutants, tumor vasculature was denser 
in both LLC tumor transplants (Suppl. Figure 3A and 3B) 
and prostate tumors (Figure 3A and 3B), with increased 
number of endothelial branching points (Figure 3A and 
3C). Regarding perivascular coverage, it was observed, 
despite the abundant SMA positive signal from the stroma 
surrounding each prostatic gland, that eJag1OE tumor 
vasculature presented considerably more smooth muscle 
cells attached to the endothelial wall than the respective 
controls (Figure 3A and 3D; Suppl. Figure 3A and 3C). 
Not surprisingly, tumor vasculature of eJag1cKO mutants 
was the opposite of what was observed in the gain-of-
function mutants: sparser (Suppl. Figure 3A and 3D; 
Figure 3A and 3E), with reduced ramification (Figure 
3F), and decreased number of perivascular SMA positive 
cells (Suppl. Figure 3A and 3E; Figure 3A and 3G). From 
Figure 3 it is also clear that there are no major differences 
in tumor vasculature between early (18 wks) and late (24 
wks) stages of prostate tumor development.
Tumor endothelial pericyte coverage was also 
investigated by immunostaining for pdgfr-β and ng-2 [20]. 
Interestingly, no significant differences were observed 
in pericyte coverage with any of the markers, in either 
TRAMP.eJag1OE or TRAMP.eJag1cKO relative to the 
respective controls (Suppl. Figure 4A-4C). In contrast, 
in the LLCs transplant model, we observed significantly 
increased and decreased levels of endothelial pdgfr-β 
coverage in OE mutants and KO mutants, respectively 
(Suppl. Figure 5).
Tumor vessel functionality in terms of perfusion and 
leakage was also analyzed by biotinylated lectin perfusion 
and Evans’ Blue dye, respectively (Figure 4 and suppl. 
Figure 6). Over-expression of Jag1 in the endothelium 
was associated with an increased number of perfused, 
lectin-containing vessels, whereas endothelial Jag1 
loss-of-function led to a significant decrease in vessel 
perfusion relative to the respective controls. Moreover, 
Evans’ Blue extravasation was significantly reduced in 
eJag1OE mutants while eJag1cKO mutants presented an 
increased vascular extravasation area. These differences in 
tumor vascular phenotypes were observed in both tumor 
models used, prostatic tumors [early (18wks) and late (24 
wks) stages, Figure 4] as well as LLC subcutaneous tumor 
transplants (Suppl. Figure 6). 
Taken together, endothelial Jag1 over-expression led 
to the formation of a dense, mature, and more functional 
tumor vascular plexus, that contributes to increased tumor 
growth and progression. Conversely, endothelial Jag1 
loss-of-function led to a sparse, immature, and poorly 
functional neo-vessel network that substantially inhibits 
tumor growth. 
Endothelial Jagged1 elicits changes in the 
transcription profile of angiocrine factors of 
endothelial and perivascular tumor associated 
cells
In order to better understand the molecular 
mechanisms behind the tumor vascular phenotypes 
observed in eJag1OE and eJag1cKO mutants, we 
performed RT-qPCR analysis of selected genes (Figure 5). 
RNA was extracted from ECs (Lin- (ter119-cd45-) cd31+) 
and vSMC cells (Lin- (ter119-cd45-) cd146+cd31-) FACS 
sorted from prostate samples collected at early and late 
stages of tumor development (Figure 5A). 
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ECs specific gene transcription (Figure 5B and 
Suppl. Figure 7A), revealed that the levels for Pdgfb 
transcription, encoding PDGF-B, the endothelial ligand 
for PDGFRβ, which controls the recruitment of pericytes, 
was not significantly altered in either of the mutants 
(Figure 5B), even though a significant down-regulation 
in eJag1cKO early stage prostate samples was observed 
(Suppl. Figure 7A). Tek (encoding the Tie2 receptor 
tyrosine kinase) which regulates vascular permeability 
and maturation [21] was downregulated in eJag1cKO 
mutants and increased in gain-of-function mutants at both 
time points. Regarding vascular endothelial growth factor 
receptor-1 (Vegfr1/Flt1) transcription in prostate tumor 
samples we observed a down-regulation in TRAMP.
eJag1OE and an up-regulation in TRAMP.eJag1cKO. In 
contrast, Vegfr-2 (Vegfr2/Kdr/Flk1) levels were positively 
modulated by endothelial Jagged1, with up-regulation 
and down-regulation in OE and KO prostate samples, 
respectively. 
Furthermore, mural cell specific transcription 
analysis (Figure 5C and Suppl. Figure 7B) revealed a 
downregulation of Jag1, Notch3 and HeyL (perivascular 
Figure 4: Prostate tumor vascular perfusion and extravasation in TRAMP endothelial-specific Jag1 mutants. A. Lectin 
(red) and PECAM-1 (green) confocal immunostaining (20x amplification) (maximum intensity projections) of TRAMP.eJag1OE and 
TRAMP.eJag1cKO mutants, to evaluate the co-localization of both signals, indicative of vessel perfusion. B. Percentage of perfused area 
in the total vascular area (given by vascular density measurements) showing increased and decreased lectin labeling in the endothelial Jag1 
over-expression and loss-of-function vasculature, respectively. C. Evans’ Blue (red) and PECAM-1 (green) confocal immunostaining (20x 
amplification) images (maximum intensity projections) showing the extravasation areas. D. Percentage of vascular extravasation area in 
the total vascular area, showing decreased Evans’ Blue staining in TRAMP.eJag1OE, and increased in TRAMP.eJag1cKO mutants. DAPI 
(blue) stains nuclei. Error bars represent SEM; *** represents p < 0.001.
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cell Notch effector) in eJag1cKO and an upregulation 
in eJag1OE mutants prostates. Additionaly, PdgfrB 
(encoding PDGFRβ) levels were not altered in response to 
endothelial Jagged1 modulation, as already demonstrated 
by protein staining for the receptor. Ang1 (perivascular 
ligand for Tie2 receptor), was up-regulated in OE and 
down-regulated in KO mutants, On the contrary, Ang2 
(antagonistic ligand for Tie2 receptor) was down-regulated 
in OE and up-regulated in KO mutants, 
These results indicate that Jag1 modulation in the 
endothelium is able to ellicit changes in the expression 
profiles of angiocrine factors that regulate angiogenesis 
and the recruitment of mural cells.
Modulation of neo-vasculature of prostatic tumors 
leads to alterations in local hypoxic levels
After characterizing the neo-vasculature of two 
different tumor models in endothelial Jag1 specific 
mutants, we aimed to understand how the different vascular 
phenotypes were able to cause such significant differences 
in progression of prostatic cancer in mice. Therefore, in 
order to evaluate tumor hypoxia, immunostaining for 
Hif1α was performed in prostatic samples from TRAMP 
eJag1 mutants. As can be observed in Figure 6A and 6B, 
eJag1OE mutants presented increased levels of Hif1α, 
Figure 5: Transcription profile of angiocrine factors by endothelial and perivascular tumor associated cells in TRAMP 
endothelial-specific Jag1 mutants. RNA was isolated from prostates collected at the end-point, and gene transcript analysis was 
performed by quantitative real-time RT-PCR for genes involved in angiogenesis. A. ECs (Lin- (cd45- ter119-) cd31+) and vSMCs (Lin- 
(cd45- ter119-) cd146+cd31-) sorted populations for specific gene transcription analysis. B. ECs specific relative gene transcription. C. 
vSMCs specific relative gene transcription. Gene transcript levels were normalized to PECAM-1 mRNA levels, and the house-keeping gene 
β-actin was used as endogenous control. Blue bars represent the gene expression levels of samples collected from eJag1OE mutants, and 
orange bars the gene expression levels from eJag1cKO mutants, relative to the respective controls. D. Representative images of Vegfr-2 
immunofluorescence (green) (20x amplification) in TRAMP endothelial-specific Jag1 mutants. E. Quantification of Vegfr-2 positive area 
per field (pixel2) demonstrating increased stained areas in TRAMP.eJag1OE and decreased staining in TRAMP.eJag1cKO relative to 
respective controls. DAPI (blue) stains nuclei. Error bars represent SEM; * represents p < 0.05; ** represents p < 0.01; *** represents p < 
0.001.
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whereas eJag1cKO show decreased levels, relative to the 
respective controls, in either early (18 wks) or late (24 
wks) stages of tumor progression. 
In addition, hypoxyprobe was administered to mice 
prior to dissection in order to visualize the tumor areas 
with low oxygen pressure (pO2 = 10 mmHg) (Figure 6C). 
The response observed was consistent with Hif1α staining 
in both TRAMP.eJag1OE, with stronger and extended 
areas of positive staining, and TRAMP.eJag1cKO 
mutants, that presented only weak and localized staining. 
Transcript levels of Hif1α mRNA were also analyzed by 
qRT-PCR (Figure 6D). Hif1α mRNA levels varied in the 
same manner as the protein staining, with up-regulation 
in OE and down-regulation in KO mutants, but only in 
an early stage (18 wks). Surprisingly, in a late stage (24 
wks) no differences were observed between the different 
mutants and the respective controls.
Endothelial Jagged1 induces proliferation and 
inhibits apoptosis in the surrounding tumor 
tissues
To better understand the metabolic changes in 
prostatic tumor development caused by altered vascular 
supply, cellular apoptosis and proliferation were addressed 
by immunostaining for active caspase 3 and ki67, 
respectively, on prostate samples from TRAMP.eJag1 
mutants (Figure 7). Endothelial Jag1 overexpression 
in TRAMP mice (TRAMP.eJag1OE) led to decreased 
apoptosis (Figure 7A and 7B) and increased cellular 
proliferation (Figure 7A and 7C). On the other hand, 
endothelial Jag1 loss-of-function (TRAMP.eJag1cKO) 
resulted in increased cellular apoptosis (Figure 7A and 7D) 
and decreased proliferation (Figure 7A and 7E).
Moreover, we profiled the transcription of several 
important cell-cycle regulatory genes in TRAMP.eJag1 
prostate samples (Figure 7F). There was up-regulation and 
down-regulation of the cell-cycle stimulating genes, Ccna 
(encoding for Cyclin A), Ccnd2 (encoding for CyclinD2), 
and c-myc, in OE and KO samples, respectively. 
Conversely, the opposite response was observed in 
the cell-cycle inhibitors, Cdkn1b (p27, encoding for 
Cyclin-Dependent Kinase Inhibitor 1B) and Cdkn1c 
(p57, encoding for Cyclin-Dependent Kinase Inhibitor 
1C): in TRAMP.eJag1OE prostate samples Cdkn1c was 
down-regulated while in TRAMP.eJag1cKO both kinase 
inhibitors were up-regulated. 
Modulation of endothelial Jag1 leads to alterations 
in epithelial-to-mesenchymal transition (EMT)
Lastly, we intended to investigate if the alterations in 
vascular supply of the prostate tumors, and consequently 
altered metabolism of tumor cells, would contribute to 
increased and/or decreased pressure for the acquisition of 
an invasive phenotype and to epithelial-to-mesenchymal 
transition. To this purpose, we performed immunostaining 
for the epithelial adhesion marker, E-cadherin, and for 
Snail, a transcription factor known for the induction of 
EMT [22], in the prostatic lesions of TRAMP mice. 
Over-expression of endothelial Jag1 (TRAMP.
eJag1OE) was associated with substantial loss of 
E-cadherin expression (Figure 8A and 8B) and increased 
expression of Snail (Figure 8A and 8C) relative to the 
respective controls. Conversely, both Snail and Slug 
mRNA expression levels were increased in these mutants 
(Figure 8F). In contrast, loss of endothelial Jag1 (TRAMP.
eJag1cKO) was associated with increased E-cadherin 
expression (Figure 7A and 7D) and decreased Snail 
expression (Figure 8A and 8E), relative to the respective 
controls. In these mutants the levels of mRNA expression 
of both Snail and Slug were also decreased (Figure 8F). 
We also analyzed tgf-β transcription levels, since it is a 
known Jagged1 dependent regulator of EMT [23], and 
observed increased and decreased transcription in OE and 
KO prostates, respectively (Figure 8F). 
Endothelial Jagged1 exerts its angiogenic function 
through Notch4/Hey1 and its angiocrine function 
through Notch3/Hey1 influencing tumor cell 
proliferation and de-differentiation
Having previously established that endothelial 
Jagged1 is able to activate Notch4 in a physiological 
angiogenic response [11], we wanted to confirm this in a 
tumor setting. To do it, we immunostained the intracellular 
domain of Notch4 (N4ICD) in our TRAMP.eJag1 mutants 
and co-localized it with PECAM to evaluate endothelial 
activation of Notch4 (Suppl. Figure 8). In TRAMP.
eJag1OE prostates we observed increased double positive 
staining for N4ICD and Pecam (Suppl. Figure 8A and 8B) 
whereas in TRAMP.eJag1cKO prostates N4ICD staining 
was decreased in the endothelium (Suppl. Figure 8A and 
8C). 
In our previous study [11], Hey1 was the main 
Notch effector found downstream of Jagged1/Notch4 
signaling. Therefore we aimed to quantify Hey1 in the 
vasculature of eJag1 mutants. As shown in Figure 9, in 
TRAMP.eJag1OE mutants prostates there were increased 
levels of Hey1 staining in the endothelium, while in 
TRAMP.eJag1cKO prostates they were decreased (Figure 
9A and 9B). Interestingly, we observed increased and 
decreased Hey1 staining in tumor cells adjacent to the 
vessels (Figure 9A and 9C), in OE and KO samples, 
respectively, relative to controls. Additionally, Hey1 
modulation by endothelial Jagged1 was confirmed at the 
transcript level (Figure 9D and 9E) in both ECs specific 
and whole prostate mRNA analysis. TRAMP.eJag1OE 
mutants presented Hey1 up-regulation in ECs (Figure 9D) 
and in whole prostate (Figure 9E), whereas eJag1cKO 
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Figure 6: Prostate tumor hypoxic levels in TRAMP endothelial-specific Jag1 mutants. A. Representative images of Hif1α 
immunofluorescence (green) (20x amplification) (maximum intensity projections) in TRAMP endothelial-specific Jag1 mutants (OE and 
KO). B. Quantification of Hif1α positive area per field (pixel2) demonstrating increased stained areas in TRAMP.eJag1OE and decreased 
staining in TRAMP.eJag1cKO relative to respective controls. C. Hypoxypyprobe immunohistochemical staining, in early (18 wks) and 
late (24 wks) stages of tumor progression, showing strong positive staining in TRAMP.eJag1OE while TRAMP.eJag1cKO mutants present 
weak positive signal, compared with controls (TRAMP Ctrl). D. Relative fold Hif1α mRNA expression showing increased expression 
in TRAMP.eJag1OE and decreased expression in TRAMP.eJag1cKO mutants, at 18 weeks of age. DAPI (blue) stains nuclei. Error bars 
represent SEM; * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001.
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Figure 7: Prostate cellular apoptosis and proliferation in TRAMP endothelial-specific Jag1 mutants. A. Representative 
images of active Caspase3 (green) and Ki67 (red) immunofluorescence staining (20x amplification) (maximum intensity projections) in 
TRAMP endothelial-specific Jag1 mutants (OE and KO). B. Prostatic lesions of TRAMP.eJag1OE mutants presented decreased percentage 
of active caspase3 positive area per field, relative to control (100%), either at 18 as at 24 weeks of age. C. Prostate samples from TRAMP.
eJag1OE presented increased percentage of Ki67 positive area per field, relative to control (100%), at both time points (18 and 24 wks) D. 
Prostatic lesions of TRAMP.eJag1cKO mutants presented increased percentage of active caspase3 positive area per field, relative to control 
(100%), at 18 and 24 weeks of age. E. Prostate samples from TRAMP.eJag1cKO presented decreased percentage of Ki67 positive area per 
field, relative to control (100%), at both time points (18 and 24 wks). F. Relative fold mRNA expression of cell cycle regulatory genes in 
TRAMP.eJag1OE and TRAMP.eJag1cKO mutants, at 24 weeks of age. DAPI (blue) stains nuclei. Error bars represent SEM; * represents 
p < 0.05; ** represents p < 0.01; *** represents p < 0.001.
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Figure 8: Epithelial-to-mesenchymal transition in prostate lesions of TRAMP endothelial-specific Jag1 mutants. 
A. Representative images of E-cadherin (green) and Snail (red) immunofluorescence staining (20x amplification) (maximum intensity 
projections) in TRAMP.eJag1OE and TRAMP.eJag1cKO mutants. B. Decreased percentage of E-cadherin per field in TRAMP.eJag1OE 
mutants, relative to respective controls (100%), at 18 and 24 weeks of age. C. Increased Snail positive area per field in OE mutants, relative 
to respective controls (100%). D. Increased percentage of E-cadherin per field in TRAMP.eJag1cKO mutants, relative to respective controls 
(100%), at 18 and 24 weeks of age. E. Decreased Snail positive area per field in KO mutants, relative to respective controls (100%). F. 
Relative fold of Snail, Slug and Tgf-β mRNA expression, demonstrating increased expression in the prostate of TRAMP.eJag1OE mutants 
whereas in TRAMP.eJag1cKO mutants prostate their expression is decreased at 24 weeks of age. DAPI (blue) stains nuclei. Error bars 
represent SEM; * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001.
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Figure 9: Hey1 transcription and expression and Notch3 intracellular domain (N3ICD) expression in prostate lesions 
of TRAMP endothelial-specific Jag1 mutants. A. Representative images of Hey1 (red) and Pecam (green) immunofluorescence 
staining (40x amplification) (maximum intensity projections) in TRAMP.eJag1OE and TRAMP.eJag1cKO mutants. White arrows indicate 
Hey1 expression in endothelial cells. B. Quantification of endothelial Hey1 positive area per field (%-relative to control) in TRAMP.
eJag1OE (left) and TRAMP.eJag1cKO (right), demonstrating increased and decreased double positive staining for Hey1/Pecam in eJag1 
mutants, respectively. C. Quantification of whole prostate Hey1 positive area per field (pixel2), demonstrating increased and decreased areas 
in OE (left) and KO (right) mutants, respectively. D. and E. ECs specific and whole prostate Hey1 transcription analysis in TRAMP.eJag1 
prostates. F. Representative images of N3ICD (green), E-cadherin (blue) and Ki-67 (red) immunofluorescence staining (40x amplification) 
(maximum intensity projections) in TRAMP.eJag1OE and TRAMP.eJag1cKO mutants. G. Quantification of N3ICD positive area per field 
(pixel2), demonstrating increased and decreased areas, relative to controls, of eJag1OE and eJag1cKO prostates, respectively. DAPI (blue) 
stains nuclei. Error bars represent SEM; * represents p < 0.05; ** represents p < 0.01; *** represents p < 0.001.
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mutants presented a down-regulation response.
Given the significant activation of Notch signaling, 
by Hey1 transcription and expression, observed in tumor 
cells adjacent to the vasculature, we hypothesized that a 
specific Notch receptor was being activated by endothelial 
Jagged1. Endothelial Jagged1 has been shown to be able 
to activate Notch3 in adjacent perivascular cells [24]. 
Additionally, high levels of Notch3 have been described 
in prostate cancer cells with high metastatic potential [25]. 
Therefore, we hypothesized that endothelial Jagged1 could 
also be acting as an angiocrine factor activating Notch3 
in adjacent tumor cells, and consequently regulating 
proliferation and de-differentiation. To test this hypothesis, 
we immunostained TRAMP.eJag1 samples for N3ICD 
concomitantly with Ki67 and E-cadherin (Figure 9F 
and 9G). TRAMP.eJag1OE mutants presented increased 
staining for N3ICD whereas eJag1cKO mutants presented 
decreased staining, relative to controls. Remarkably, as 
shown in Figure 9F, the tumor areas that display activated 
Notch3 staining also have increased ki67 positive staining 
and loss of E-cadherin. 
DISCUSSION
In the last decades tumor angiogenesis has become 
a very active area of research, resulting in the introduction 
of anti-angiogenic drugs in cancer therapy, such as the 
anti-VEGF antibody bevacizumab [26] and the tyrosine 
kinase inhibitors like sunitinib or sorafenib [27]. Many 
other molecules have been investigated since for their 
effect on angiogenesis. Modulation of endothelial Jag1 
was previously shown to be crucial in developing retina 
vascularization [10]. The results presented here describe 
the effect of modulating endothelial Jag1 in tumor 
angiogenesis and metabolism and consequently in tumor 
development and progression. 
We observed that endothelial Jag1 over-expression 
accelerated the growing rate of LLC subcutaneous 
tumor transplants and contributed to the progression and 
development of prostate cancer in TRAMP mice. This 
effect was associated with an increase in the density and 
branching of the tumor vessels. In contrast, endothelial 
Jag1 loss-of-function delayed the growing rate of LLC 
subcutaneous transplants and inhibited the development 
of prostate lesions in TRAMP mice, by decreasing the 
density and branching of the tumor neo-vasculature. This 
appears to be consistent with a report that increased tumor 
microvascular density (MVD) constitutes a bad prognostic 
indicator in several solid tumors that induce significant 
angiogenesis [28].
From the observations in the TRAMP model, where 
there is a stepwise progression of tumor development, 
no major differences were observed in the vascular 
response between early (18 wks) and late (24 wks) stages, 
which is thought to be a consequence of the angiogenic 
switch occurring relatively early on the onset of prostatic 
lesions and therefore before 18 wks of age [29]. In this 
report we show that endothelial Jagged1 acts as a pro-
angiogenic ligand in a tumor setting, after having recently 
demonstrated this effect in a regenerative setting [11], 
where Jagged1 antagonizes Dll4 regulation of endothelial 
branching, by its ability to block Dll4/Notch1 activation 
and thus by positively regulating Vegfr-2 transcription. 
Here, we have further validated and complemented 
the mechanistic process by which endothelial Jagged1 
exerts its pro-angiogenic function, by showing that it 
not only positively regulates Vegfr-2 transcription and 
expression, but that it also negatively regulates Vegfr-1 
transcription, specifically in ECs. Accordingly, a recent 
report using a Notch decoy that specifically blocks 
Jagged ligands mediated interaction [15] has shown 
that the anti-angiogenic effect observed is likely due to 
increased secretion of the soluble form of Vegfr-1, and 
thus decreased Vegf/Vegfr-2 signaling. 
In addition, in confirming the pro-angiogenic 
function of endothelial Jagged1 in tumors, we have 
identified a new role for it in promoting blood vessel 
maturation in tumor angiogenesis, since eJag1OE tumor 
vasculature presented increased coverage of SMA+ cells, 
whereas the vasculature of eJag1KO mutants presented the 
opposite phenotype. Moreover, the ECs and SMCs specific 
mRNA levels of angpt1 (encoding angiopoetin1) and tek 
(encoding tie-2 receptor), respectively, members of one of 
the main signaling pathways involved in the recruitment 
of support cells to the vessel wall [30], also responded 
accordingly with modulation of eJag1. Additionally, 
endothelial Jagged1 was also able to positively regulate 
vSMC specific Jag1 and Notch3 and HeyL levels, 
supporting the existing model where activation of 
perivascular Notch3 and HeyL effector is essential for 
the assembly of a SM layer [24]. The contribution of 
endothelial Jagged1 to vSMC recruitment has already 
been described in other angiogenic settings [24, 31, 32]. 
Moreover, we have also suggested previously that the 
perivascular phenotype observed in eJag1 mutants can 
also be a consequence of Notch4 activation by endothelial 
Jagged1. Inclusively we have not only demonstrated 
increased and decreased levels of active Notch4 in OE 
and KO mutants, respectively, but also increased vessel 
maturation upon administration of a Notch4 specific 
agonist to WT mice [11]. Here, we have further validated 
Notch4 as a strong endothelial receptor for Jagged1. 
In tumors, pericyte coverage decrease and perturbed 
associations between pericytes and endothelial layer have 
been described [33, 34]. However, we found no significant 
alterations in pericyte number by pdgfr-β or ng-2 
immunostaining or changes in the levels of pdgfr-β mRNA 
in eJag1 mutant’s prostate tumor vasculature, suggesting 
that the observed changes in vascular maturation are 
independent of pericyte coverage. Nonetheless, in the 
LLCs transplant model, modulation of endothelial Jagged1 
produced alterations in pericyte coverage, suggesting that 
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the absence of effect on pericyte coverage by Jagged1 
function modulation seems to be prostate specific. 
Similarly, the use of a Jagged specific Notch decoy [15], 
presented the same perivascular phenotype as the one 
caused by endothelial Jagged1 loss-of-function. 
Modulation of tumor angiogenesis and maturation 
by endothelial Jagged1 led to alterations in functionality 
and permeability of tumor vessels, which ultimately may 
lead to different hypoxic and metabolic responses of tumor 
cells. Over-expression of endothelial Jag1 culminated in 
increased perfusion and decreased extravasation, while 
endothelial loss-of-function caused the tumor vasculature 
to be less perfused and leakier. This was likely to cause, 
respectively, increased and decreased delivery of oxygen 
to tumor cells. However, unexpectedly, quantification of 
Hif1α protein and mRNA levels, as well as pimonidazole- 
thiol adducts formation by hypoxyprobe administration, 
indicates that OE and KO mutant prostatic tissues have 
increased and decreased hypoxic levels, respectively. It is 
known that Hif1α is up-regulated in most prostate tumor 
tissues, compared with normal and benign prostate tissues 
[35]. Additionally, it is also established that prostate 
cancer cells have the ability to compensate the lack of 
oxygen by anaerobic glycolytic respiration [36], which 
is able to persist upon neovascularization, suggesting that 
the glycolytic phenotype arises from genetic or epigenetic 
changes [37]. 
It seems clear that from the early beginning of 
tumor epithelial transformation (demonstrated in lesions 
of TRAMP.eJag1cKO) the local concentration of oxygen 
drops in the affected areas. It is also clear that the oxygen 
concentration levels are inversely proportional to the 
degree of dysplasia. We have observed that endothelial 
Jagged1 contributes to tumor dysplasia through two 
distinct effects: a pro-angiogenic effect, increasing 
tumor vascular density, maturation and perfusion; and an 
angiocrine effect likely through Notch3/Hey1 stimulation 
of tumor cell proliferation. Therefore we propose that 
the angiogenic and angiocrine functions of endothelial 
Jagged1 both contribute to increase proliferation and 
reduce apoptosis leading to increased consumption of 
local oxygen with consequent acidotic microenvironment 
conditions and increased hypoxia. Therefore the TRAMP.
eJag1OE prostates, that present the most aggressive 
lesions, also present the lowest oxygen levels.
Moreover, numerous reports have also described a 
crosstalk between Notch and hypoxia signaling pathways 
[38]. Inclusively, the existence of a negative feed-back 
loop has been suggested, in order to prevent excessive 
hypoxic gene induction, by the ability of Hey factors to 
repress Hif1α induced gene expression [39]. This negative 
feed-back loop may explain why Hif1α mRNA levels were 
only altered in an early stage (18 wks) of prostate tumor 
development in TRAMP.eJag1 mutants since at late stages 
(24 wks) modulation of Hey1 mRNA levels may have 
caused a repressive effect.
The hyper-productive angiogenesis observed in 
the prostatic lesions of TRAMP.eJag1OE mutants, was 
associated with increased proliferation and survival of 
tumor cells and to the acquisition of a more invasive 
phenotype promoting de-diferentiation and epithelial-
mesenchymal transition (Figure 7A-7C). Accordingly, 
Jagged1 mediated activation is known to induce epithelial-
mesenchymal transition [40]. Conversely, the anti-
angiogenic phenotype observed in TRAMP.eJag1cKO 
mutants was associated with reduced proliferation of 
tumor cells and increased apoptotic events (Figure 6A, 
6D-6E) that ultimately restricted invasiveness (Figure 
7A, 7D-7E). Notably, endothelial Jagged1 regulated the 
transcription profile of several cell cycle regulatory genes: 
CyclinA, D2 and c-myc were positively regulated while 
the inhibitors of these kinases activity, Cdkn1b and c were 
negatively regulated by endothelial Jagged1 function. 
Similarly, previous studies have demonstrated that down-
regulation of Jag1 induces cell growth inhibition and S 
phase cell cycle arrest in prostate cancer cells [41]. 
The metabolic changes observed in prostate tumor 
cells that arise from altered tumor angiogenic response 
may not only be a consequence of altered support of 
nutrients and oxygen, but can also be a consequence 
of paracrine signaling. In this work we have also 
unveiled a new angiocrine effect of the Jagged1 ligand. 
Endothelial Jagged1 not only up-regulated ECs specific 
Hey1 transcription and expression but also increased its 
expression in adjacent tumor cells. In twin slides, we could 
also observe that the same Hey1 positive tumor areas 
concomitantly expressed active Notch3, had increased 
tumor cell proliferation and presented loss of epithelial 
markers, suggesting a de-differentiation phenotype. 
Therefore, we suggest that endothelial Jagged1 is able to 
regulate tumor cell metabolism by its angiocrine function 
through Notch3/Hey1. Accordingly, Jagged1 expressing 
EC- tumor cell signaling has been described in the 
regulation of colorectal cancer [42], and in the ability of 
providing chemo resistance, aggressiveness to lymphoma 
cells by activating Notch2 and consequently Hey1 in these 
adjacent cells [14]. 
The angiocrine effect combined with the pro-
angiogenic and pro-maturation function of endothelial 
Jagged1 may constitute an important therapeutic advantage 
over Dll4 based-therapies. Blockade of DLL4 was shown 
to lead to increased nonproductive tumor vasculature 
inhibiting tumor growth [5, 6]. However, long-term 
blockade of Dll4 was found to lead to the development of 
vascular neoplasms [43] and other toxicities [44]. 
In summary, this study is the first to demonstrate 
the effect of directly modulating endothelial Jag1 in 
tumor development. Notably, loss of endothelial Jag1 
not only had an inhibitory effect in the neo-angiogenic 
and maturation responses but also had an angiocrine 
effect, through inhibition of Notch3/Hey in tumor cells, 
restricting proliferation, increasing apoptosis, and 
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preventing the acquisition of an invasive phenotype 
by tumor cells, therefore inhibiting growth and 
development of subcutaneous LLC tumor transplants and 
autochthonous prostatic tumors in mice. Thus, this report 
provides substantial support for the development of novel 
therapeutic strategies against cancer based on blocking 
endothelial Jagged1 function. 
MATERIALS AND METHODS
Experimental animals
All the procedures involving animals used in this 
study were approved by the Ethics and Animal Welfare 
Committee of the Faculty of Veterinary Medicine of 
Lisbon (see Suppl. Methods). 
To obtain the gain-of-function mutants, 
heterozygous Tet-O-Jag mice were crossed with a line 
of heterozygous Tie-2-rtTA mutant mice. The double 
heterozygous offspring obtained, Tet-O-Jag; Tie-2-rtTA, 
were administered doxycicline (4mg/ml in drinking water 
from week 4), in order to activate the overexpression of 
Jag1 under the control of the Tie-2 promotor. One control 
group contained mice with the same Jag1 gain-of-function 
genotype that were not induced with doxycicline. Another 
control group consisted of TRAMP.Tet-O-Jag1.Tie-2-
rtTA- mice administered with doxycycline to discard 
possible doxycycline driven effects. No differences in 
tumor growth dynamics or tumor vascular phenotypes 
were found between the two control groups (data not 
shown). 
The loss-of-function mutant is a conditional “knock-
out” where the coding region for the DSL (Delta-Serrate-
Lag2) region of Jag1 (exon 4) is flanked by loxP sites- 
Jag1lox/lox line [45] (B6; 129S-Jag1 tm2Grid/J; The Jackson 
Laboratory). Jag1lox/+ mice were crossed with VE-
Cadherin-Cre-ERT2 mice [46] in order to obtain a Jag1lox/lox 
VE-Cadherin-Cre-ERT2 mouse line. Jag1 null endothelial 
mutants were generated upon treatment with tamoxifen 
(50mg/kg daily IP for 5 days, starting one week before the 
experiment). One control group had the same Jag1 loss-of-
function genotype but were not induced with tamoxifen. 
Another control group consisted of TRAMP.Jag1lox/lox VE-
Cadherin-Cre-ERT2- mice administered with tamoxifen to 
discard possible tamoxifen specific effects. No differences 
in tumor growth dynamics or tumor vascular phenotypes 
were found between the control groups (data not shown).
LLC subcutaneous tumor model
Lewis Lung Carcinoma (LLC) (ATCC® CRL-
1642TM) [47] cells were cultured in RPMI 1640 medium 
(Gibco 21875-034) supplemented with 10% foetal 
bovine serum (Gibco 10270-106) and 1% penicillin/
streptomycin (Gibco 15140-122) in 100mm tissue culture 
dishes (Corning 734-1705) coated with poly-D-Lysine 
Hydrobromide (Sigma P7280) at 37 °C in a humidified 
atmosphere of 95% air and 5% CO2. 
When cells reached subconfluence, they were 
detached by 5 min treatment with 0,25% trypsin-EDTA 
(Gibco 25200-056) and resuspended in PBS to a cell 
concentration of 1×107/ml. For the transplant tumor model, 
cells (1×106/mouse) were inoculated subcutaneously, in 
the right flank with the mouse under anaesthesia (2,5% 
avertin).
Tissue preparation and immunohistochemistry
Subcutaneous tumor transplants were collected at 
day 14th after LLC injection and, in the TRAMP model, 
prostates were dissected at 18 or 24 weeks of age. 
For histopathological analysis, prostates were fixed 
in 10% buffered formalin solution for 48 h, dehydrated 
in alcohol, cleared in xylene, embedded in paraffin, 
sectioned at 3μm and stained with hematoxylin (Fluka 
AG Buchs SG Switzerland) and eosin Y (Sigma, St. 
Louis, MO). The sections were then analysed blindly by 
a pathologist (CP) and scored according to the literature 
[18]. Tumor samples from both models, were also fixed 
with 4% paraformaldehyde (PFA) solution at 4°C for 1h, 
cryoprotected in 15% sucrose, embedded in 7,5% gelatin, 
frozen in liquid nitrogen and cryosectioned at 10 and 
20μm. 
To examine vascular density and vessel maturity a 
rat monoclonal anti-mouse PECAM-1 (BD Pharmingen, 
San Jose, CA) and a mouse monoclonal anti-SMA Cy3 
conjugate (Sigma Aldrich, USA), combined with a donkey 
anti-rat conjugated with Alexa Fluor 488 (Invitrogen, 
Carlsbad, CA) were used. Nuclei were counterstained 
with 4’, 6’-diamidino-2-phenylindole dihydrochloride 
hydrate (DAPI; Molecular Probes, Eugene, OR). Vascular 
density is equivalent to the percentage of each tumor 
section field occupied by a PECAM-1-positive signal (as 
determined by the percentage of black pixels per field after 
transforming the RGB images into binary files). Similarly, 
as a measure of vascular maturity, mural cell recruitment 
was assessed by quantifying the percentage of PECAM-1-
positive structures lined by α-SMA-positive cells. 
To assess vascular perfusion, avertin (2,5%) 
anesthetized mice were injected with biotin-conjugated 
lectin from Lycopersicon esculentum (100µg in 100µl of 
PBS; Sigma, St. Luis, MO) via caudal vein and allowed 
to circulate for 5 minutes before perfusing the vasculature 
transcardially with 4% PFA in PBS for 3 minutes. Slides 
were stained with rat monoclonal anti-mouse PECAM-1, 
followed by Alexa 594 goat anti-rat IgG (Invitrogen, 
Carlsbad, CA). Biotinylated lectin was visualised with 
Streptavidin-Alexa 488 (Invitrogen, Carlsbad, CA). 
Tumor perfusion area was quantified by determining the 
percentage of PECAM-1-positive structures that were co-
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localized with Alexa 488 signals. 
To analyse vascular extravasation, avertin 
anesthetized mice were injected with 1% Evans Blue 
dye solution (Sigma, St. Luis, MO) via caudal vein, and 
perfused transcardially 5 minutes later with 4% PFA in 
PBS for 3 minutes. Tissue sections were stained with rat 
monoclonal anti-mouse PECAM-1, followed by Alexa 488 
goat anti-rat IgG. Tumor vascular extravasation area was 
quantified by determining the tumor section field of Evans 
Blue red positive signal per vessel area (given by vascular 
density measurements).
For evaluation of hypoxic levels a rabbit anti-
Hif1α antibody was used (Abcam, Cambridge, UK). 
Additionally, HypoxyprobeTM-1 Plus Kit (Hypoxyprobe, 
Inc, USA) was used to detect cells with low oxygen 
pressure (pO2 = 10 mmHg), in paraffin embedded 
sections.
For quantification of cellular apoptosis and 
proliferation, a rabbit anti-active caspase3 (Cell signaling 
Technology) and an Alexa-570 conjugated mouse anti-
Ki67 (eBiosciences Inc., CA, USA) antibodies were used.
For the assessment of epithelial to mesenchymal 
transition, an Alexa-488 conjugated mouse anti-E-cadherin 
and a goat polyclonal anti-Snail (Abcam, Cambridge, UK) 
antibodies were used, respectively.
Additional primary antibodies used were goat 
anti-Jagged1 (Sigma), rat anti-Vegfr-2 (Cell signalling 
Technology), Alexa-488 conjugated rabbit anti- NG-2 
(Milipore) rabbit anti-Hey1 (Milipore), rabbit anti-
N3ICD and goat anti-N4ICD (Santa Cruz Biotechnology). 
Additional secondary antibodies used were Alexa-647 
donkey anti-goat, anti-rat and anti-rabbit (Invitrogen, 
Carlsbad, CA).
Quantitative transcriptional analysis
For whole prostate analysis, tumor samples were 
collected at the endpoint of each experiment and snap 
frozen for RNA extraction (Qiagen, Hilden, Germany).For 
ECs and vSMCs specific analysis, samples were collected 
at the endpoint of each experiment and prepared for FACS 
sorting. ECs and mural cells were sorted directly into the 
lysis buffer of the RNeasy Micro Kit (Qiagen). Total RNA 
was isolated according to manufacturer’s protocol. A total 
of 100 ng RNA per reaction (ECs and vSMCs) and 400 ng 
per reaction (whole prostate) was used to generate cDNA 
with the SuperScript III First Strand Synthesis Supermix 
Q RT-PCR Kit (Invitrogen, CA). Relative quantification 
real-time PCR analysis was performed as described [48] 
using Sybergreen Fastmix ROX dye (Qiagen). Primer pair 
sequences are available on request. The housekeeping 
gene β-actin was used as endogenous control.
Flow cytometry
For flow cytometric analysis and sorting of ECs 
(Lin- (cd45- ter119-) cd31+) and mural cells (Lin- (cd45- 
ter119-) cd146+ cd31-) [49], prostates were collected 
and finely dissected into small pieces (2-4 mm). Then, 
the samples were digested into 1 ml solution of 1% 
collagenase (Sigma) and 2,4U/ml of dispase (Gibco, Life 
Technologies) incubation at 37ºC, with agitation, for 
2h30 min. DNAse I (Sigma) was added during digestion 
to eliminate DNA residues. After washing, digested cells 
were then subjected to immunostaining with anti-mouse 
ter-119 PE-Cy7, anti-mouse cd45 PE-Cy7 (Affymetrix, 
eBioscience), anti-mouse cd31 FITC and anti-mouse 
cd146 PE (BD Pharmingen). After washing, cells were 
sorted in FACS Aria III cytometer and analyzed using BD 
FlowJo software (Version 10.0, BD Bioscience). 
For demarcating and sorting ECs and mural cells, 
first standard quadrant gates were set, subsequently to 
differentiate cd31+ (>103 log FITC fluorescence) and 
cd146+ (>10 log PE fluorescence) cells from the Lineage 
negative population (≤102 log PE-Cy7 fluorescence).
Statistical analysis 
All data processing (except most common prostatic 
lesion) was carried out using the Statistical Package for 
the Social Sciences software, version 17.0 (SPSS v. 17.0; 
Chicago, IL). Statistical analyses were performed using 
Mann-Whitney-Wilcoxon test and Student’s t-test. 
Scores of the most common histopathological 
prostatic lesions were analyzed with the GLM procedure 
of Statistical Analysis System (SAS Institute Inc. v.9.1.3 
2009; Cary, USA). The analyses were carried out within 
group, with a linear model including the effects of 
time (weeks 18 and 24), endothelial Jag1 modulation 
(eJag1OE and eJag1cKO vs. respective controls) and their 
interaction. 
All results are presented as mean ± SEM. P-values 
< 0.05, <0.01 and <0.001 were considered significant 
(indicated in the figures with *) and highly significant 
(indicated with ** and ***), respectively. 
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